Patient-Derived Acute Myeloid Leukemia (AML) Models

A unique platform that accurately recapitulates leukemia phenotypes in vivo, the AML Patient-Derived Xenograft (PDX) models are designed to promote the optimal leukemia conditions.

REQUEST A QUOTE

 

 

micetech@jax.org | 1.800.422.6423 (US) | 1.207.288.5845 (International)

Model Specifications

Summary of AML Model Specifications

Model Number Diagnosis Mutational Profile NSG™-SGM3 Engraftment Ara-C Responsive
J000106132* Acute Myelocytic Leukemia FLT3+, NPM1+, DNMT3A+, and IDH1+ 20% AML at 8 weeks Yes
J000106134* Acute Myelocytic Leukemia, M4 FLT3+ and NPM1+ 45% AML at 8 weeks Yes
J000106566* Acute Myelocytic Leukemia TP53+ 35% AML at 8 weeks Yes
J000106124* Acute Myelocytic Leukemia, secondary No mutations identified 80% AML at 8 weeks Not Characterized
J000106143* Acute Myelocytic Leukemia TP53+ and CUX1+ 20% AML at 8 weeks Not Characterized
J000106565* Acute Myelocytic Leukemia M4/M5 FLT3 ITD+, FLT3 TKD+, and NPM1+ 15% AML at 8 weeks Not Characterized
J000106569* Acute Myelocytic Leukemia FLT3-ITD+ and NPM1+ 10% AML at 8 weeks Not Characterized

*Passaged Models

J000106132* Data

J000106132*, Positive for FLT3, NPM1, DNMT3A and IDH1

*Passaged Model

AML Studies - J000106132*, Positive for FLT3, NPM1, DNMT3A and IDH1

Percent Engraftment of AML J000106132

AML Studies - Percent Engraftment of AML J000106132

PDX J000106132 averages 20% engraftment at 8 weeks and 70% at 12 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

Ara-C Response in AML Model J000106132

AML Studies - Ara-C Response in AML Model J000106132

J000106132 AML NSG-SGM3™ mice. Growth rate of AML samples detected in peripheral blood in the presence or absence of Ara-C.  Mice were engrafted with human AML cells (hCD33+) and treated +/- Ara-C (30mg/kg) for five consecutive days.

J000106134* Data

J000106134*, Positive for FLT3 and NPM1

*Passaged Model

AML Studies - J000106134*, Positive for FLT3 and NPM1

Percent Engraftment of AML J000106134

AML Studies - Percent Engraftment of AML J000106134

PDX J000106134 averages 45% engraftment at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

ARA-C RESPONSE IN AML MODEL J000106134

AML Studies - ARA-C RESPONSE IN AML MODEL J000106134

J000106134 AML NSG™-SGM3 mice. Growth rate of AML samples detected in peripheral blood in the presence or absence of Ara-C.  Mice were engrafted with human AML cells (hCD33+) and treated +/- Ara-C (30mg/kg) for five consecutive days.

J000106566* Data

J000106566*, Positive for TP53

*Passaged Model

AML Studies - J000106566*, Positive for TP53

Percent Engraftment of AML J000106566

AML Studies - Percent Engraftment of AML J000106566

PDX J000106566 averages 10% engraftment at 6 weeks and 35% at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

ARA-C RESPONSE IN AML MODEL J000106566

AML Studies - ARA-C RESPONSE IN AML MODEL J000106566

J000106566 AML NSG™-SGM3 mice. Growth rate of AML samples detected in peripheral blood in the presence or absence of Ara-C. Mice were engrafted with human AML cells (hCD33+) and treated +/- Ara-C (30mg/kg) for five consecutive days.

J000106124* Data

J000106124*, No Mutations Identified

*Passaged Model

AML Studies - J000106124*, No Mutations Identified

Percent Engraftment of AML J000106124

AML Studies - Percent Engraftment of AML J000106124

PDX J000106124 averages averages 80% engraftment at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106143* Data

J000106143*, Positive for TP53 and CUX1

*Passaged Model

AML Studies - J000106143*, Positive for TP53 and CUX1

Percent Engraftment of AML J000106143

AML Studies - Percent Engraftment of AML J000106143

PDX J000106143 averages 50% engraftment at 12 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106565* Data

J000106565*, Positive for FLT3 ITD, FLT3 TKD, and NPM1

*Passaged Model

AML Studies - J000106565*, Positive for FLT3 ITD, FLT3 TKD, and NPM1

Percent Engraftment of AML J000106565

AML Studies - Percent Engraftment of AML J000106565

PDX J000106565 averages 15% engraftment at 8 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

J000106569* Data

J000106569*, Positive for FLT3-ITD and NPM1

*Passaged Model

AML Studies - J000106569*, Positive for FLT3-ITD and NPM1

Percent Engraftment of AML J000106569

AML Studies - Percent Engraftment of AML J000106569

PDX J000106569 averages 10% engraftment at 8 weeks and 57% at 12 weeks post engraftment in peripheral blood of NSG™-SGM3 mice.

FAQ & References

Frequently Asked Questions

  1. In which mouse models were engraftment levels tested?

    2. The currently available models are confirmed to engraft in the NSG™-SGM3 mice.

  2. What engraftment levels do you typically see?

    3. Greater than 5% AML in the peripheral blood of NSG™-SGM3 mice 10-16 weeks post engraftment.

  3. How many AML engrafted mice can be included per order or on study with JAX?

    4. A minimum of 15 mice is required. Approximately 100-500 mice in total can be engrafted depending on the model of interest.

  4. What are passaged AML models?

    5. Some AML tumor models in our portfolio were passaged in vivo. This approach allows JAX to continuously supply the models and retain inventory for use in further studies at later dates if needed.

  5. How long does it take to confirm AML engraftment?

    6. The average time to confirm AML engraftment in the peripheral blood of NSG™-SGM3 mice is 8 weeks post injection.

References

  • Elizabeth C. Townsend, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice, Cancer Cell, Volume 29, Issue 4, 2016, Pages 574-586, ISSN 1535-6108
  • Wunderlich et al. 2010. Leukemia. 24(10):1785-8. [PMID: 20686503]